SIC
IKT icon

SJS Investment Consulting’s Inhibikase Therapeutics IKT Stock Holding History

SJS Investment Consulting’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65 Buy
32
+23
+256% +$41 ﹤0.01% 2692
2026
Q1 		$16 Buy
+9
New +$16 ﹤0.01% 2390

Other funds holding IKT

AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SJS Investment Consulting's IKT Position: Q2 2026 in Review

SJS Investment Consulting increased its Inhibikase Therapeutics (IKT) stake by 256% in Q2 2026, buying an estimated $41 and bringing the position to 32 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

SJS Investment Consulting first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • SJS Investment Consulting held 32 shares of Inhibikase Therapeutics worth $65 as of Q2 2026.
  • SJS Investment Consulting bought 23 Inhibikase Therapeutics shares in Q2 2026, an estimated $41.
  • Inhibikase Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2692 holding.
  • SJS Investment Consulting first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.